Joanne Waldstreicher

BioOHDSI Publications
Jon Duke

Joanne Waldstreicher, MD
Chief Medical Officer
Johnson & Johnson

Joanne Waldstreicher, M.D., is Chief Medical Officer, Johnson & Johnson. In this role, she has oversight across pharmaceuticals, devices and consumer products for safety, epidemiology, clinical and regulatory operations transformation, collaborations on ethical science, and technology and R&D policies, including those related to clinical trial transparency and compassionate access. She chairs the R&D development pipeline review committee for Janssen, the pharmaceuticals group of Johnson & Johnson, and supports Device and Consumer Development committees. Joanne is also a Faculty Affiliate of the Division of Medical Ethics, Department of Population Health, New York University School of Medicine.

Among her prior roles, Joanne was responsible for late-stage development in neuroscience, cardiovascular disease and metabolism at Janssen. Before joining Johnson & Johnson in 2002, she headed Endocrinology and Metabolism clinical research at Merck Research Laboratories, overseeing development programs in atherosclerosis, obesity, diabetes, urology and dermatology. She was honored with the Key Innovator Award, among other distinctions.

Joanne received both the Jonas Salk and Belle Zeller scholarships from the City University of New York, and graduated Summa Cum Laude from Brooklyn College. She graduated Cum Laude from Harvard Medical School, completed her internship and residency at Beth Israel Hospital, and her endocrinology fellowship at Massachusetts General Hospital. She has received numerous awards and scholarships, and is an active scientific author. In 2016, the National Association of Female Executives named her Healthcare Champion of the Year. Joanne combines broad experience in science and medicine with a passion for advancing transparency and ethics, with a goal of improving the lives of patients and consumers worldwide.

Berlin JA, Morris S, Rockhold F, Askie L, Ghersi, D, Waldstreicher J. Bumps and Bridges on the Road to Responsible Sharing of Clinical Trial Data. Clinical Trials 11:7-12, 2014.

Committee on Strategies for Responsible Sharing of Clinical Trial Data, IOM (Institute of Medicine). Discussion Framework for Clinical Trial Data Sharing: Guiding Principles, Elements, and Activities. Washington, DC: The National Academies Press. 2014.

Morris S, Childers K, Berlin JA, Waldstreicher J. The Need for Even Further Progress with Clinical Trial Data Sharing Efforts: Patients are Waiting. Clinical Investigation 5(6): 531-533, 2015

Committee on Strategies for Responsible Sharing of Clinical Trial Data. Sharing clinical trial data: maximizing benefits minimizing risk. Washington, DC: National Academies Press, 2015.

Caplan, Arthur L, Bateman-House, Alison, Waldstreicher, J. Compassionate Use: A Modest Proposal. American Society of Clinical Oncology educational book. 35:e2-e4 (# 2124842), 2016.

Krumholz, Harlan M., Waldstreicher, J. The Yale Open Data Access (YODA) Project – A Mechanism for Data Sharing. NEJM 375:403-405, 2016.

Krumholz, Harlan M., Bourne, Philip E., Kuntz, Richard E., Paz, Harold L., Terry, Sharon F., Waldstreicher, J. Data Acquisition, Curation, and Use For a Continuously Learning Health System – A Vital Direction for Health and Health Care. Perspectives; Expert Voices in Health & Health Care. National Academies of Medicine, 2016.

Krumholz, Harlan M., Terry, Sharon F., Waldstreicher, J. Data Acquisition, Curation, and Use For a Continuously Learning Health System –Vital Directions from the National Academy of Medicine. JAMA 316(16): 1669-1670, 2016.

Waldstreicher J, Johns ME. Managing conflicts of interest in industry-sponsored clinical research: more physician engagement is required. JAMA 317(17):1751 doi:10.1001/jama.2017.4160

Arthur Caplan, PhD, Alison Bateman-House, MPH, PhD, Joanne Waldstreicher, MD, Lisa Fedor, BS, Ramana Sonty, MBBS, MPhil, PhD, Tito Roccia, MD, Jon Ukropec, PhD, Rick Jansson, PhD, MBA. A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug. The Compassionate Use Advisory Committee (Comp AC). Therapeutic Innovation & Regulatory Science. March, 2018.